首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

2088150

個人化醫療市場預測（2034 年）－按產品、技術、應用、最終用戶和地區分類的全球分析

Personalized Medicine Market Forecasts to 2034 - Global Analysis By Product (Personalized Therapeutics, Personalized Diagnostics and Personalized Care Solutions), Technology, Application, End User and By Geography

出版日期: 2026年07月11日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球個人化醫療市場預計到 2026 年將達到 6,713 億美元，並在預測期內以 8.8% 的複合年成長率成長，到 2034 年將達到 1.3,181 兆美元。

個人化醫療是一種現代醫療保健方法，它根據個人獨特的生物學和環境特徵，客製化預防、診斷和治療方案。透過整合基因資訊、生活方式和臨床數據，個人化醫療能夠提供更精準有效的醫療解決方案。透過基因組分析、預測建模和生物標記評估等工具，醫生可以更早識別健康風險，並選擇更精準的治療方案。這不僅提高了康復率，還減少了無效治療和副作用。個人化醫療摒棄了「一刀切」的治療模式，提升了患者照護質量，支持更明智的決策，並建構了一個更有效率、數據驅動、以個別需求為中心的醫療保健體系。

據美國國立衛生研究院 (NIH) 稱，「我們所有人」研究計劃到 2026 年將招募超過 873,000 名參與者，並將產生 414,000 個全基因組序列。

慢性病盛行率增加

癌症、糖尿病、心臟病和呼吸系統疾病等慢性病的日益流行，正顯著推動著個人化醫療市場的發展。這些疾病需要長期照護和個人化治療策略，但由於患者個別反應的差異，傳統方法往往效果不佳。個人化醫療透過提供基於基因組成、環境和生活方式的客製化療法來應對這項挑戰。這有助於改善疾病管理並降低併發症的發生率。預期壽命的延長、飲食習慣的改變以及久坐不動的生活方式，都加劇了疾病發病率的上升，導致全球對精準、個性化的醫療保健解決方案的需求日益成長，以改善長期治療效果。

個人化醫療的研發和實施高成本。

開發和實施個人化醫療的高昂成本是限制市場發展的主要因素。基因定序、分子診斷和生物資訊學等先進技術需要大量的資金投入。醫療機構還必須建造專門的基礎設施，並聘用能夠分析複雜資料集的專業人員。此外，個人化療法和精準藥物研發的成本高於傳統療法。這些成本加重了經濟負擔，限制了個人化醫療的普及，尤其是在醫療預算有限的中低收入地區。因此，由於許多醫療系統難以承擔高昂的實施和維護成本，個人化醫療的整體普及速度正在放緩。

基因組研究和先進診斷技術的擴展

基因組研究的拓展和精準診斷技術的進步為個人化醫療市場創造了巨大的成長機會。基因定序、生物標記辨識和分子分析的進步，加深了我們對疾病在個體層面進展的理解。這使得基於患者基因譜的診斷工具和治療方案能夠更加精準。來自公共和私營部門的資金投入不斷增加，推動了該領域的快速創新。大規模基因組資料庫的擴充將進一步提高疾病風險和治療結果預測的準確性。總而言之，這些趨勢為先進診斷解決方案的開發和精準醫療在全球範圍內的廣泛應用創造了巨大的潛力。

倫理考量與基因歧視的風險

倫理問題和潛在的基因歧視對個人化醫療市場構成嚴峻挑戰。基因資訊高度敏感，引發了人們對隱私、知情同意和潛在濫用的擔憂。基因資訊顯示患病風險較高的人可能會面臨雇主和保險公司的歧視。這些擔憂可能會降低人們接受基因檢測或共用個人健康數據的意願。此外，關於數據所有權和知情同意的懸而未決的爭論進一步加劇了問題的複雜性。這些倫理挑戰有可能損害公眾信任，並減緩個人化醫療解決方案在全球的普及和發展。

新型冠狀病毒（COVID-19）的影響：

新冠疫情加速了先進醫療解決方案的普及，對個人化醫療市場產生了重大影響。追蹤病毒變異和了解個別患者反應的迫切需求，促使人們更加依賴基因測序、快速檢測和標靶治療。各國政府和醫療系統加大了對精準醫療技術的投資，以支持疫苗研發和疾病監測。疫情也促進了數據分析和生物技術在醫療決策中的應用。然而，臨床試驗、供應鏈和常規醫療服務的中斷造成了暫時的挫折。儘管面臨這些挑戰，這場危機最終還是改善了全球個人化醫療的長期成長前景。

在預測期內，個人化診斷領域預計將佔據最大的市場佔有率。

預計在預測期內，個人化診斷領域將佔據最大的市場佔有率，因為它在疾病的早期檢測和有效治療策略的製定中發揮著至關重要的作用。該領域涉及對基因數據、生物標記和分子指標的分析，以深入了解個體的健康狀況和風險。基因組檢測、成像系統和伴隨診斷工具等先進診斷技術的日益普及，正在鞏固該領域的市場地位。人們對醫療保健日益成長的關注以及對準確及時診斷的需求，也是推動其成長的因素。透過提供對標靶治療至關重要的訊息，個人化診斷是精準醫療的核心，能夠顯著改善患者的治療效果。

在預測期內，研究和學術機構領域預計將呈現最高的複合年成長率。

在預測期內，由於科學研究和學術機構在創新和科學進步中發揮至關重要的作用，預計其成長率將最高。這些機構深度參與基因組學研究、生物標記辨識和臨床研究，而這些研究正是精準醫療發展的基礎。政府和私營機構不斷增加的財政支持，推動了基因組學、蛋白質組學和生物資訊學等領域研究活動的拓展。與製藥和生物技術公司的緊密合作，有助於加速個人化療法的研發。此外，將研究成果轉化為實際臨床應用的重視，也推動了該領域在全球範圍內的強勁成長。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健體系、創新技術的快速應用以及對研發活動的大力投入。該地區擁有許多大型製藥和生物技術公司，以及高度發展的基因組學研究設施和支持性的監管政策。美國透過精準診斷和個人化醫療的廣泛應用，為市場做出了重大貢獻。此外，政府對基因組學研究舉措的支持和資助進一步鞏固了該地區的主導地位，使北美成為全球個人化醫療的重要市場。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療衛生體系的快速發展、醫療支出的不斷成長以及人們對精準醫療解決方案日益增強的認知。中國、印度和日本等主要國家慢性病負擔的加重，推動了對先進診斷和個人化醫療的需求。對生物技術、基因組學和數位醫療技術的大力投資，進一步促進了成長。政府支持醫療創新和現代化的各項計劃也發揮了重要作用。此外，該地區龐大的人口基礎和不斷擴大的臨床研究活動，使其成為個人化醫療應用的重要成長中心。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域分類
- 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
競爭性標竿分析
- 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

F. Hoffmann-La Roche Ltd
Illumina, Inc.
Thermo Fisher Scientific Inc.
Novartis AG
Pfizer Inc.
Abbott Laboratories
Qiagen
GE Healthcare, Inc.
AbbVie Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AstraZeneca
Sanofi
Takeda Pharmaceutical Company Ltd.
Amgen Inc.
Merck & Co., Inc.
Guardant Health

簡介目錄圖表

Product Code: SMRC37818

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $671.3 billion in 2026 and is expected to reach $1318.1 billion by 2034 growing at a CAGR of 8.8% during the forecast period. Personalized medicine is a modern healthcare method that customizes prevention, diagnosis, and treatment according to an individual's unique biological and environmental profile. It integrates genetic information, lifestyle habits, and clinical data to deliver more accurate and effective medical solutions. Through tools like genomic analysis, predictive modeling, and biomarker evaluation, doctors can identify health risks earlier and select therapies with greater precision. This reduces ineffective treatments and adverse reactions while improving recovery rates. By moving away from generalized treatment approaches, personalized medicine enhances patient care quality, supports better decision-making, and promotes a more efficient, data-driven healthcare system focused on individual needs.

According to the U.S. National Institutes of Health (NIH), the All of Us Research Program has enrolled over 873,000 participants as of 2026, with 414,000 whole-genome sequences generated.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The rising incidence of chronic illnesses including cancer, diabetes, heart diseases, and respiratory disorders is significantly boosting the personalized medicine market. These conditions require long-term care and individualized treatment strategies, which conventional approaches often fail to deliver effectively due to differences in patient response. Personalized medicine addresses this gap by offering customized therapies based on genetic makeup, environment, and lifestyle patterns. This leads to improved disease control and fewer complications. Increasing life expectancy, changing dietary habits, and sedentary lifestyles are contributing to higher disease rates, thereby increasing the need for precise, patient-specific healthcare solutions worldwide for better long-term outcomes.

Restraint:

High cost of personalized medicine development and implementation

High expenditure associated with personalized medicine development and deployment acts as a significant market limitation. Advanced processes such as gene sequencing, molecular diagnostics, and bioinformatics require substantial financial investment. Healthcare organizations must also build specialized infrastructure and employ trained experts to interpret complex datasets. Furthermore, individualized therapies and precision drug development are more costly than conventional treatment methods. These expenses reduce affordability and restrict adoption, particularly in low and middle income regions with limited healthcare funding. Consequently, the overall expansion of personalized medicine is slowed, as many healthcare systems struggle to support the high costs involved in implementation and maintenance.

Opportunity:

Expansion of genomic research and precision diagnostics

Growing genomic research and advancements in precision diagnostics offer a strong growth opportunity for the personalized medicine market. Improvements in gene sequencing, biomarker identification, and molecular analysis are enhancing the understanding of how diseases develop at an individual level. This enables more accurate diagnostic tools and treatment plans based on a patient's genetic profile. Increased funding from public and private sectors is driving rapid innovation in this area. The expansion of large genomic databases further supports better prediction of disease risks and therapy outcomes. Overall, this trend is creating significant potential for advanced diagnostic solutions and wider adoption of precision healthcare worldwide.

Threat:

Ethical concerns and genetic discrimination risks

Ethical issues and the possibility of genetic discrimination pose a serious challenge to the personalized medicine market. Since genetic data is highly sensitive, its use raises concerns about privacy protection, consent, and possible misuse. Individuals may face discrimination from employers or insurance providers if their genetic information indicates a higher risk of diseases. This fear can reduce willingness to undergo genetic testing or share personal health data. Additionally, unresolved debates about data ownership and informed consent create further complexity. These ethical challenges may weaken public trust and slow down the adoption and development of personalized medicine solutions worldwide.

Covid-19 Impact:

The COVID-19 outbreak significantly influenced the personalized medicine market by speeding up the use of advanced healthcare solutions. The urgent need to track virus variations and understand individual patient responses increased reliance on genomic sequencing, rapid testing, and targeted therapeutic strategies. Governments and health systems invested more in precision medicine technologies to support vaccine research and disease monitoring. The pandemic also boosted the use of data analytics and biotechnology in healthcare decision-making. However, interruptions in clinical studies, supply networks, and routine medical services caused temporary setbacks. Despite these challenges, the crisis ultimately enhanced the long-term growth outlook for personalized medicine worldwide.

The personalized diagnostics segment is expected to be the largest during the forecast period

The personalized diagnostics segment is expected to account for the largest market share during the forecast period as it plays a vital role in identifying diseases at an early stage and supporting effective treatment decisions. This segment involves analyzing genetic data, biomarkers, and molecular indicators to better understand individual health conditions and risks. The growing use of advanced diagnostic technologies, including genomic testing, imaging systems, and companion diagnostic tools, has enhanced its market position. Increasing focus on preventive healthcare and the need for precise, timely diagnosis are also driving its growth. By providing essential insights for targeted therapies, personalized diagnostics serves as the core of precision medicine and improves patient outcomes significantly.

The research & academic institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the research & academic institutes segment is predicted to witness the highest growth rate because they play a key role in innovation and scientific advancement. These organizations are heavily involved in studying genomics, identifying biomarkers, and conducting clinical research that supports precision medicine development. Growing financial support from governments and private entities is enabling expansion of research activities in fields like genomics, proteomics, and bioinformatics. Strong collaboration with pharmaceutical and biotechnology companies is helping accelerate the development of personalized treatments. Additionally, the emphasis on converting research findings into real clinical applications is driving strong growth in this segment worldwide.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare system, rapid adoption of innovative technologies, and strong investment in research activities. The region is home to major pharmaceutical and biotechnology firms, along with highly developed genomic research facilities and supportive regulatory policies. The United States significantly contributes through widespread use of precision diagnostics and individualized therapies. Additionally, government support and funding for genomic research initiatives strengthen the region's leadership position, making North America the key market for personalized medicine globally.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR because of rapid healthcare system development, rising medical spending, and increasing awareness of precision healthcare solutions. The growing burden of chronic illnesses in major countries like China, India, and Japan is boosting the need for advanced diagnostics and customized therapies. Strong investments in biotechnology, genomics, and digital healthcare technologies are further enhancing growth. Government programs supporting healthcare innovation and modernization are also contributing significantly. Moreover, the region's large population base and expanding clinical research activities make it a key growth hub for personalized medicine adoption.

Key players in the market

Some of the key players in Personalized Medicine Market include F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., Novartis AG, Pfizer Inc., Abbott Laboratories, Qiagen, GE Healthcare, Inc., AbbVie Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., AstraZeneca, Sanofi, Takeda Pharmaceutical Company Ltd., Amgen Inc., Merck & Co., Inc. and Guardant Health.

Key Developments:

In April 2026, GE HealthCare announced an expanded collaboration with DeepHealth, Inc, to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and women's health.

In November 2025, Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Products Covered:

Personalized Therapeutics
Personalized Diagnostics
Personalized Care Solutions

Technologies Covered:

Genomics & Sequencing
Pharmacogenomics
Proteomics & Metabolomics
Digital Health & AI Integration
Biomarker Analysis

Applications Covered:

Oncology
Neurology
Cardiology
Infectious Diseases
Rare & Genetic Disorders

End Users Covered:

Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutes
Pharmaceutical & Biotech Companies

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Medicine Market, By Product

5.1 Personalized Therapeutics
5.2 Personalized Diagnostics
5.3 Personalized Care Solutions

6 Global Personalized Medicine Market, By Technology

6.1 Genomics & Sequencing
6.2 Pharmacogenomics
6.3 Proteomics & Metabolomics
6.4 Digital Health & AI Integration
6.5 Biomarker Analysis

7 Global Personalized Medicine Market, By Application

7.1 Oncology
7.2 Neurology
7.3 Cardiology
7.4 Infectious Diseases
7.5 Rare & Genetic Disorders

8 Global Personalized Medicine Market, By End User

8.1 Hospitals & Clinics
8.2 Diagnostic Laboratories
8.3 Research & Academic Institutes
8.4 Pharmaceutical & Biotech Companies

9 Global Personalized Medicine Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 F. Hoffmann-La Roche Ltd
12.2 Illumina, Inc.
12.3 Thermo Fisher Scientific Inc.
12.4 Novartis AG
12.5 Pfizer Inc.
12.6 Abbott Laboratories
12.7 Qiagen
12.8 GE Healthcare, Inc.
12.9 AbbVie Inc.
12.10 Eli Lilly and Company
12.11 Bristol-Myers Squibb Company
12.12 Gilead Sciences, Inc.
12.13 AstraZeneca
12.14 Sanofi
12.15 Takeda Pharmaceutical Company Ltd.
12.16 Amgen Inc.
12.17 Merck & Co., Inc.
12.18 Guardant Health

簡介目錄圖表

List of Tables

Table 1 Global Personalized Medicine Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Personalized Medicine Market Outlook, By Product (2023-2034) ($MN)
Table 3 Global Personalized Medicine Market Outlook, By Personalized Therapeutics (2023-2034) ($MN)
Table 4 Global Personalized Medicine Market Outlook, By Personalized Diagnostics (2023-2034) ($MN)
Table 5 Global Personalized Medicine Market Outlook, By Personalized Care Solutions (2023-2034) ($MN)
Table 6 Global Personalized Medicine Market Outlook, By Technology (2023-2034) ($MN)
Table 7 Global Personalized Medicine Market Outlook, By Genomics & Sequencing (2023-2034) ($MN)
Table 8 Global Personalized Medicine Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
Table 9 Global Personalized Medicine Market Outlook, By Proteomics & Metabolomics (2023-2034) ($MN)
Table 10 Global Personalized Medicine Market Outlook, By Digital Health & AI Integration (2023-2034) ($MN)
Table 11 Global Personalized Medicine Market Outlook, By Biomarker Analysis (2023-2034) ($MN)
Table 12 Global Personalized Medicine Market Outlook, By Application (2023-2034) ($MN)
Table 13 Global Personalized Medicine Market Outlook, By Oncology (2023-2034) ($MN)
Table 14 Global Personalized Medicine Market Outlook, By Neurology (2023-2034) ($MN)
Table 15 Global Personalized Medicine Market Outlook, By Cardiology (2023-2034) ($MN)
Table 16 Global Personalized Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 17 Global Personalized Medicine Market Outlook, By Rare & Genetic Disorders (2023-2034) ($MN)
Table 18 Global Personalized Medicine Market Outlook, By End User (2023-2034) ($MN)
Table 19 Global Personalized Medicine Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 20 Global Personalized Medicine Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
Table 21 Global Personalized Medicine Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
Table 22 Global Personalized Medicine Market Outlook, By Pharmaceutical & Biotech Companies (2023-2034) ($MN)